PReS13-SPK-1253: Challenges in nursing care with the new biologics for JIA
نویسندگان
چکیده
منابع مشابه
PReS13-SPK-1253: Challenges in nursing care with the new biologics for JIA
Sam was diagnosed with extended oligoarticular Juvenile Idiopathic Arthritis at the age of 18 months. He began Etanercept at the age of 10 years old in March 2007 after an inadequate response to non-steroidal medications, methotrexate and numerous steroid preparations. Seventeen months later he was switched to Adalimumab with the expectation that this would have an improved response for him. Sa...
متن کاملPReS13-SPK-1137: New developments in our care & understanding of JIA
Recent years have seen a rapid change in speed of translation from basic science into the clinic: the benefits of this are now being felt right across pediatric rheumatology. There is an increasing awareness that our patients need first class science to be done to answer major questions and develop better treatments: in fact patients and their families often ask why we are not making faster pro...
متن کاملPReS13-SPK-1576: Unmeet needs in JIA treatment
Conducting clinical trials in paediatric rheumatology has been difficult in the past mainly because of the lack of funding for academic studies and the lack of interest by pharmaceutical companies for the small and nonrewarding paediatric market. The situation changed dramatically few years ago with the introduction of the Best Pharmaceuticals for Children Act in USA and of a specific legislati...
متن کاملPReS13-SPK-1469: Juvenile scleroderma
Juvenile localized scleroderma, also known as morphea, is the more frequent subtype of scleroderma in childhood. It comprises a group of distinct conditions which involve the skin and subcutaneous tissues. They range from very small plaques of fibrosis involving only the skin, to diseases which may cause significant functional and cosmetic deformity. The most widely used classification divides ...
متن کاملPReS13-SPK-1034: looking for new monogenic forms of lupus
We can expect that a better understanding of the pathogenesis of systemic lupus erythematosus (SLE) will eventually lead to improved treatments for this devastating disorder (’translational medicine’). And if lupus is not a single disease entity, then different treatment regimens might be appropriate in different patients (’personalized medicine’). As one approach to improving our understanding...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Pediatric Rheumatology
سال: 2013
ISSN: 1546-0096
DOI: 10.1186/1546-0096-11-s2-i2